Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Retreatment of Recurrent Dupuytren's Contracture with Xiaflex
NCT01498640Phase 4Completed
- Sponsor
- Endo International plc
- Start
- Mar 2012
- Primary completion
- Oct 2013
- Modality
- Therapeutic Enzymes
- Countries
- 4
01
Overview
Phase 4, open-label trial of collagenase clostridium histolyticum in Dupuytren's disease (2 arms), sponsored by Endo International plc. Primary endpoints: Clinical Success at 30 days, Percent Change From Baseline in Degree of Contracture at 30 days and 1 more. Started Mar 2012; status: completed.
02
Drugs
collagenase clostridium histolyticum
03
Conditions
Dupuytren's disease
Beyond the preview
Go deeper on NCT01498640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01498640.